mental and behavioural disorder due to use of hallucinogen相关文献:
The Therapeutic Potential of Psilocybin.
Lowe H, Toyang N, Steele B, Valentine H, Grant J, Ali A, Ngwa W, Gordon L.
Molecules. 2021 May 15;26(10):2948. doi: 10.3390/molecules26102948.
PMID:34063505
Psychedelics and Psychedelic-Assisted Psychotherapy.
Reiff CM, Richman EE, Nemeroff CB, Carpenter LL, Widge AS, Rodriguez CI, Kalin NH, McDonald WM; the Work Group on Biomarkers and Novel Treatments, a Division of the American Psychiatric Association Council of Research.
Am J Psychiatry. 2020 May 1;177(5):391-410. doi: 10.1176/appi.ajp.2019.19010035. Epub 2020 Feb 26.
PMID:32098487
Psychedelics.
Kelmendi B, Kaye AP, Pittenger C, Kwan AC.
Curr Biol. 2022 Jan 24;32(2):R63-R67. doi: 10.1016/j.cub.2021.12.009.
PMID:35077687
Hallucinogens in Mental Health: Preclinical and Clinical Studies on LSD, Psilocybin, MDMA, and Ketamine.
De Gregorio D, Aguilar-Valles A, Preller KH, Heifets BD, Hibicke M, Mitchell J, Gobbi G.
J Neurosci. 2021 Feb 3;41(5):891-900. doi: 10.1523/JNEUROSCI.1659-20.2020. Epub 2020 Nov 30.
PMID:33257322
Psilocybin-assisted therapy for depression: A systematic review and meta-analysis.
Haikazian S, Chen-Li DCJ, Johnson DE, Fancy F, Levinta A, Husain MI, Mansur RB, McIntyre RS, Rosenblat JD.
Psychiatry Res. 2023 Nov;329:115531. doi: 10.1016/j.psychres.2023.115531. Epub 2023 Oct 11.
PMID:37844352
Reviewing the Potential of Psychedelics for the Treatment of PTSD.
Krediet E, Bostoen T, Breeksema J, van Schagen A, Passie T, Vermetten E.
Int J Neuropsychopharmacol. 2020 Jun 24;23(6):385-400. doi: 10.1093/ijnp/pyaa018.